Combination Therapy for SARS-CoV-2 Using Segmented Antiviral Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for COVID-19, caused by SARS-CoV-2, face challenges due to the virus's high transmissibility, mutation, and limited success of vaccine-based approaches, necessitating alternative therapeutic strategies to effectively prevent and treat coronavirus-associated diseases.
Innovation Solution
Administering a combination of peramivir, cidofovir, or nevirapine with other antiviral agents such as reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, or viral DNA polymerase inhibitors, either simultaneously or sequentially, to reduce SARS-CoV-2 replication and proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccine-based approaches are used to mitigate COVID-19, then immunity may be provided, but the continual mutation of the virus causes the strategy to be in a continuous catch-up cycle with limited success
Solution Approach 1:
The treatment approach is segmented into multiple independent antiviral agents (peramivir, cidofovir, or nevirapine combined with other antiviral agents from different classes) that target different stages of the viral replication cycle, rather than relying on a single vaccine-based approach
Solution Approach 2:
The patent employs composite therapeutic strategies by combining multiple antiviral agents with different mechanisms of action (neuraminidase inhibitor, nucleotide analog, non-nucleoside reverse transcriptase inhibitor, protease inhibitor, integrase inhibitor, or DNA polymerase inhibitor) to create a multi-targeted treatment regimen that addresses viral mutation adaptability
2Reliability
If combination therapy with multiple antiviral agents is administered, then viral replication is more effectively inhibited, but the treatment complexity increases
Solution Approach 1:
Multiple antiviral agents with different mechanisms of action are merged into a single combination therapy regimen, where peramivir, cidofovir, or nevirapine is administered together with other antiviral agents to simultaneously target multiple stages of viral replication
Solution Approach 2:
The combination therapy regimen is designed to perform multiple functions: peramivir inhibits neuraminidase, cidofovir or nevirapine inhibits reverse transcriptase, and additional agents target protease, integrase, or DNA polymerase, creating a multi-functional treatment that addresses various viral replication processes
Data Source
AI summary
The present disclosure provides methods of treating coronavirus-associated diseases in an individual comprising administering to the individual an effective amount of peramivir, cidofovir, or nevirapine and an effective amount of a second antiviral agent. Also provided are methods of treating coronavirus-associated diseases in an individual comprising administering to the individual an effective amount of nevirapine and an effective amount of valacyclovir and/or nevirapine. Also provided are formulations and methods of delivering the formulations to an individual.